3 active not recruiting, 1 recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Refractory Primary Malignant Central Nervous System Neoplasm: new trials by email Literature Review of Refractory Primary Malignant Central Nervous System Neoplasm trials Research Report on Refractory Primary Malignant Central Nervous System Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors SC-CAR4BRAIN - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma | Phase 1 | Active not recruiting | Seattle Children's Hospital | 72 | 2023-05-05 | 2026-10-13 |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 63 | 2022-01-28 | 2026-09-11 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
Central Nervous System Neoplasms (2) · Diffuse Intrinsic Pontine Glioma (2) · Hepatoblastoma (2) · Osteosarcoma (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Sarcoma, Ewing (2) · Wilms Tumor (2) · Adrenocortical Carcinoma (1) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Renal Cell (1) · Ependymoma (1) · Glioma (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Neoplasms, Neuroepithelial (3) · Nervous System Diseases (3) · Nervous System Neoplasms (3) · Brain Diseases (2) · Brain Stem Neoplasms (2) · Central Nervous System Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2)
Biopsy (1) · CBLC137 (1) · Fluid Therapy (1) · Pharmacogenomic Variants (1) · Specimen Handling (1) · cabozantinib (1) · ulixertinib (1)
National Cancer Institute (NCI) (2) · Children's Oncology Group (1) · Seattle Children's Hospital (1)
United States (4) · Australia (1) · Puerto Rico (1)
David S Ziegler (1) · Kieuhoa T Vo (1) · Rebecca Ronsley, MD (1) · Srivandana Akshintala (1)
U10CA180886 (2), UM1CA228823 (1)